laurabbook@gmail.com

*December 2023* Note: Amivantamab and Lazertinib may soon receive approval as a first-line treatment for EGFR+ lung cancer. A supplemental biologics license application and new drug application seeking the approval of amivantamab-vmjw (Rybrevant) plus lazertinib as frontline therapy for the treatment of patients with locally advanced or metastatic non–small cell lung…

*December 2023* Non-small cell lung cancer (NSCLC), the most common form of lung cancer, is often diagnosed at an advanced stage. About half the time, it has already spread around the body and has reached stage 4. The standard treatment for most patients with metastatic NSCLC is systemic therapy (drugs that spread throughout…

*November 2023* Note: Allosteric inhibitors are an exciting new possibility to treat osimertinib resistance but are still in preclinical stage of development. Researchers at Dana-Farber Cancer Institute have developed a promising new drug candidate, EAI-432, to treat non-small cell lung cancers (NSCLC)driven by mutations in the EGFR gene, particularly the L858R mutation…

*December 2023* In this episode of Lung Cancer Considered, host Dr. Stephen Liu leads a discussion on the current first-line treatment options for EGFR-mutant non-small cell lung cancer, including how new data from FLAURA2 and MARIPOSA may influence treatment approaches. Listen to podcast here.

*November 2023* Although biomarker testing is crucial for determining optimal targeted therapies for patients with advanced non–small cell lung cancer (NSCLC), the time between conducting these tests and receiving results poses challenges for both oncologists and patients, according to Stephen V. Liu, MD. “There are cases where we need to…

*November 2023* In this video, Hossein Borghaei, MS, DO, chief of Thoracic Medical Oncology, professor in the Department of Hematology/Oncology at Fox Chase Cancer Center, and the Gloria and Edmund M. Dunn Chair in Thoracic malignancies, provides an overview on his presentation given at the 18th Annual New York Lung Cancers Symposium®.…

*November 2023* This is a very interesting video presentation consisting of lung cancer experts and EGFR Resisters co-founder Jill Feldman discussing the treatment options after osimertinib (Tagrisso) faillure. It covers: Importance of liquid and tissue biopsies to check for new mutations chemo is standard of care amivantamab +lazertinib ADCs clinical…

*November 2023* In this phase 3, international, open-label trial, we randomly assigned in a 1:1 ratio patients with EGFR-mutated (exon 19 deletion or L858R mutation) advanced non–small-cell lung cancer (NSCLC) who had not previously received treatment for advanced disease to receive osimertinib (80 mg once daily) with chemotherapy (pemetrexed plus either…